Connect Biopharma Holdings Ltd 8-K

What Happened

• Connect Biopharma Holdings Limited announced its financial results for the three months ended March 31, 2026 in a press release issued on May 12, 2026. The company filed an 8-K (Item 2.02) to disclose these quarterly results; the press release is attached as Exhibit 99.1 to the filing.

Key Details

• Filing date: May 12, 2026; reporting period: three months ended March 31, 2026 (Q1 2026).
• Disclosure type: Item 2.02 — Results of Operations and Financial Condition; Exhibit 99.1 contains the press release.
• The Form 8-K was signed by Lisa Peraza, Senior Vice President, Finance, on behalf of the company.

Why It Matters

• This 8-K provides the company’s official quarterly results disclosure (earnings/quarterly results and related financial condition). Investors should review the attached press release (Exhibit 99.1) for specific metrics such as revenue, net income/loss, cash position and any commentary on guidance or business updates. The filing is a timely, primary source for Q1 2026 financial information.